Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • £0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Blogs > Strategy > Is Diversification the Right Strategy for Big Pharma?

Is Diversification the Right Strategy for Big Pharma?

June 18, 2018 | Strategy

Jane weber brubaker

Top pharma companies may be well-advised to look beyond their core business – prescription branded pharmaceuticals – to other healthcare sectors as a hedge of protection against looming threats including:

  • Declining revenues as a result of patent expiries
  • Impending launches of biosimilars
  • Slow R&D productivity
  • Pricing pressures
  • Payer restrictions

A new trend report from Datamonitor Healthcare by analyst Amanda Micklus, Big Pharma Diversification Strategies, evaluates opportunities in 10 healthcare sectors by looking at indicative profit potential (IPP), a metric derived by multiplying the total market value of a sector by its average profit margin.

Using this calculation, the prescription branded pharmaceuticals sector has the highest IPP by a factor of almost five compared to the next highest sector, but other sectors such as medical devices and diagnostics, and OTC/consumer health also have high profit potential. “The Big Pharma companies that have already diversified into this area, and are remaining there, have done well in terms of growing revenue,” says Micklus.

The report classifies the top 15 pharmaceutical companies into three categories based on strategy:

  • Focused – 90 percent of revenue from pharmaceuticals (ex. Bristol-Myers Squibb)
  • Intermediate – 50 to 90 percent of revenue from pharmaceuticals; balance from non-pharmaceutical businesses (ex. GlaxoSmithKline)
  • Diversified – < 50 percent of revenue from branded pharmaceuticals; more than half of revenue from non-pharmaceutical businesses (ex. Johnson & Johnson)

Here, we’ll recap highlights from three case studies that illustrate each of the strategies.

Bristol-Myers Squibb – Focused Strategy

Bristol-Myers Squibb put a stake in the ground in 2007, shifting its focus to specialty medicines and biologics after a restructuring. “Our unique BioPharma strategy … leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm,” the company’s website touts.

To accumulate the cash needed to support M&A activity in its new focus areas, the company divested several businesses, including ConvaTec, its wound care business, and Lantheus, which produces nuclear and ultrasound cardiovascular diagnostic imaging agents. The acquisition of Medarex, an antibody drug discovery firm, added two key immuno-oncology products to the company’s biologics portfolio.

Between 2013 and 2017, revenue from biologics increased (CAGR +30 percent) relative to small molecules (CAGR -2 percent). Small molecules today represent a decreasing portion of the pie relative to biologics.

GlaxoSmithKline – Intermediate Strategy

GlaxoSmithKline’s (GSK) pharmaceutical business dropped to 74 percent of total revenues between 2016 and 2017, down from 80 percent between 2013 and 2015. Revenue from the pharmaceutical business is largely comprised of small molecules, with vaccines a growing category.

GSK’s consumer health brands include household names such as Sensodyne, Nicorette, and Theraflu. The consumer health business has been growing as a proportion of total revenue, taking share away from small molecules, according to Datamonitor Healthcare. The consumer health sector averaged 21 percent of the company’s total revenue from 2013 to 2017.

Solidifying its position further, GSK recently cut a deal for $13bn with Novartis, it’s partner in a consumer health joint venture, to take over the entire project. Emma Walmsley, GSK CEO, stated that the proposed deal would “allow GSK shareholders to capture the full value of one of the world’s leading consumer healthcare businesses.” (Scrip, March 27, 2018).

Johnson & Johnson – Diverisified Strategy

Dominic Caruso, Johnson & Johnson’s  (J&J) chief financial officer, says the company should not be described as a pharma, devices, or consumer company. Rather, it is a healthcare company. Consistent with this view, on average, only 44 percent of the firm’s revenue over the past five years came from prescription pharmaceuticals.

The company’s consumer health business is large part of its overall strategy, in spite of some setbacks including a major recall of OTC analgesics in 2010. Since then, J&J has been gradually regaining market share from private labels. CNN reported in May that the company was hit with a $25.75 million verdict related to its Baby Powder product after a patient contracted pleural mesothelioma.

J&J plans large-scale marketing campaigns focused on six core areas: OTC, oral health, women’s health, wound care, baby care, and beauty, hoping to rebuild its consumer business back to its previous standing. It also plans to ramp up direct to consumer sales through digital channels.

These examples illustrate three distinct approaches that Big Pharma may employ for maximum growth and competitiveness. Companies must continue to respond to the challenges facing the industry as a whole, and craft flexible strategies that capitalize on their strengths while minimizing risks.

Related Products

Big Pharma Diversification Strategies
Big Pharma Outlook 2026

FacebookTweetPin

Related posts:

As Rare Disease Drugs Multiply, So Must Creative Ways to Pay for Them
Strategy

As Rare Disease Drugs Multiply, So Must Creative Ways to Pay for Them

  • February, 19 2019
  • 1371

Patients suffering from one of the many hundreds of rare diseases known to exist have a better chance than ever of finding a treatment. Companies large and small continue to invest, given high unmet need and very targeted populations. Progress must contin

New Pharma Models for a new Healthcare Era
Strategy

New Pharma Models for a new Healthcare Era

  • January, 10 2019
  • 1377

When Google in November 2018 hired David Feinberg to head up its healthcare efforts, it was just the latest sign of the tech giant’s ambitions in the sector. Feinberg was previously president and CEO of Geisinger, among the US’ largest and most forward-lo

Is January’s M&A a flash in the pan, or does it signal sustained dealmaking heat
Strategy

Is January’s M&A a flash in the pan, or does it signal sustained dealmaking heat

  • January, 10 2019
  • 1285

2019 started with a bang for pharma M&A: by January 7, $82 billion worth of shopping had been announced. Bristol Myers Squibb’s $74 billion cash and stock offer for Celgene on New Year’s day is the fourth-largest deal ever. It was followed days later

Related Content
Read more
lorem

  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.
US Tax Reform Jump-Starts M&A Activity in 2018 Biopharma companies have the cash and are ready to deal

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.
By continuing to use the website, you consent to our use of cookies.
OkRead more
Scroll to top